NouBio Inc is enabling mass market adoption of A.I. cell-based human blood and therapies; scaling new disease treatments, defense innovations, and age-reversal longevity technology applications. 

We are entering a new era where A.I. is creating novel cell-based blood and therapies for age reversal or the extension of human lifespan but the sector is paralysed and remains trapped at lab scale. 

NouBio's three pillar deeptech and A.I. platform solutions enable low cost ($10/L) industrial production and mass market adoption of custom, scalable, cell-based blood and therapies without any deep operational losses or prohibitive unit economics.

NouBio's first deeptech pillar NouSerum drops cell-based blood and therapy production costs by 95%, removes animal diseases, with no global shortages, or price volatility.

NouBio can create custom cell-based blood and therapies with our data science & machine learning A.I. tools in gene/protein/DNA/RNA editing, cell isolation protocols, therapy enhancing formulas, & POCs of hollow fiber biocomputers with circulatory flow.

NouBio's final deeptech Bio-Microcarrier eliminates 40% of biomanufacturing time, with no cell removal needed, and increased cell density.

NouBio ensures that cell-based therapies and the entire cellular longevity sector no longer remains paralysed or trapped in the lab.   

Without NouBio's solutions companies in this industry are leaving billions of potential economic value on the table & an inability to scale the next generation of disease treatments or age reversal technologies.

NouBio is industrialising A.I. cellular human longevity by dropping production costs to under $10/L.

Enabling mass market adoption of the next generation in disease treatments, defense innovations, and age reversal technologies to extend human lifespan. 
 
NouBio Inc raised VC investment from Big Idea Ventures & angel investors.

NouBio Inc

Org chart

Teams

Offices